National Health (Originator Brand) Amendment Determination 2020 (No. 1) (PB 9 of 2020) (Cth)

PB 9 of 2020

National Health (Originator Brand) Amendment Determination 2020 (No. 1)

National Health Act 1953

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Determination under subsection 99ADB (6B) of the National Health Act 1953.

Dated 29 January 2020

THEA DANIEL

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

1. Name of Determination

(1)     This Determination is the National Health (Originator Brand) Amendment Determination 2020 (No. 1).

(2)     This Determination may also be cited as PB 9 of 2020.

1. Commencement

This Determination commences on 1 February 2020.

1. Amendments to PB 100 of 2015

Schedule 1 amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015).

Schedule 1     Amendments

(section 3)

[1]                   Schedule 1, (table item 80)

Repeal the items:

80	Exemestane	Aromasin
80A	Ezetimibe	Ezetrol
80B	Ezetimibe and rosuvastatin	Rosuzet Composite Pack
80C	Ezetimibe with simvastatin	Vytorin

Substitute:

80	Exemestane	Aromasin
80A	Ezetimibe	Ezetrol
80B	Ezetimibe and rosuvastatin	Rosuzet Composite Pack
80C	Ezetimibe with atorvastatin	Atozet
80D	Ezetimibe with simvastatin	Vytorin

[2]                   Schedule 1, (after table item 228)

Insert:

228A Tiotropium Spiriva Spiriva Respimat